Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825289 · ClinicalTrials.gov registry record · Phase 1
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
A Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by University of Utah.
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT03825289: Active Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by University of Utah.
NCT03825289 is a Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 25 participants, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03825289, a Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib together with hydroxychloroquine may work better in treating patients with pancreatic cancer.
Primary Outcome
To determine the recommended phase II dose (RP2D) hydroxychloroquine in combination with trametinib.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Hydroxychloroquine
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What the registry record for NCT03825289 still lists
NCT03825289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower).
The record links to 7 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.
NCT03825289 reports a single indexed study location in California, Utah.
Frequently Asked Questions
What is clinical trial NCT03825289 about?
NCT03825289 is a clinical study titled "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer". This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth ...
What is the current status of trial NCT03825289?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-01-18. Estimated completion is 2029-03.
What conditions does trial NCT03825289 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Unresectable Pancreatic Carcinoma, Stage II Pancreatic Cancer.
What interventions are being tested in trial NCT03825289?
The interventions under investigation include: Trametinib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT03825289?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03825289 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03825289's enrollment target sits among peer trials
25 11th of 15 higher than 4 of 15 other Stage IV Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI